Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYQVIA in Pediatric Primary Immunodeficiency
NCT03277313Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2017
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Human normal immunoglobulin G in primary immunodeficiency disease (PID), sponsored by Takeda. Started Sep 2017; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT03277313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03277313.